PhenomeX Inc. (CELL)

NASDAQ: CELL · IEX Real-Time Price · USD
0.550
+0.028 (5.28%)
At close: Jun 8, 2023, 4:00 PM
0.540
-0.010 (-1.82%)
After-hours: Jun 8, 2023, 7:33 PM EDT
5.28%
Market Cap 41.67M
Revenue (ttm) 76.91M
Net Income (ttm) -100.03M
Shares Out 75.76M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 961,556
Open 0.540
Previous Close 0.522
Day's Range 0.525 - 0.570
52-Week Range 0.508 - 6.110
Beta n/a
Analysts Hold
Price Target 3.00 (+445.46%)
Earnings Date May 11, 2023

About CELL

PhenomeX Inc. operates as a functional cell biology company. The company enables scientists to reveal insights on cell function and obtain behavior of each cell. Its suite of tools and services offer unparalleled resolution and speed, accelerating the insights for advancing discoveries that can profoundly improve the prevention and treatment of disease. The company's platforms are used by researchers worldwide, including pharmaceutical companies and comprehensive cancer centers. PhenomeX Inc. is headquartered in Emeryville, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 17, 2020
Employees 285
Stock Exchange NASDAQ
Ticker Symbol CELL
Full Company Profile

Financial Performance

In 2022, PhenomeX's revenue was $78.60 million, a decrease of -7.96% compared to the previous year's $85.39 million. Losses were -$98.04 million, 36.7% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for CELL stock is "Hold" and the 12-month stock price forecast is $3.0.

Price Target
$3.0
(445.46% upside)
Analyst Consensus: Hold
Stock Forecasts

News

PhenomeX Launches Beacon Quest™ Optofluidic System with Opto® T Cell Profiling Workflows

Beacon Quest designed with affordable two-chip optofluidic system to accelerate the pace of scientific discovery across academic, non-profit, and government research including comprehensive single T C...

3 days ago - PRNewsWire

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities EMERYVILLE, Calif. , May 15, 2023 /PRNewswire/ -- Phen...

3 weeks ago - PRNewsWire

PhenomeX Reports First Quarter 2023 Financial Results

Company provides full year 2023 financial guidance EMERYVILLE, Calif. , May 11, 2023 /PRNewswire/ -- PhenomeX, Inc. (Nasdaq: CELL), a life sciences tools company, today reported financial results for ...

1 month ago - PRNewsWire
}

PhenomeX To Participate in 19th Annual PEGS Boston Conference & Expo

PhenomeX optofluidic and proteomic technology to be featured in several poster and podium presentations EMERYVILLE, Calif. , May 11, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell b...

1 month ago - PRNewsWire

PhenomeX to Report First Quarter 2023 Financial Results on May 11, 2023

EMERYVILLE, Calif. , April 27, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the firs...

1 month ago - PRNewsWire

PhenomeX Appoints Peter Silvester to PhenomeX Board of Directors

EMERYVILLE, Calif. , April 10, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors...

2 months ago - PRNewsWire

PhenomeX to Participate in American Association of Cancer Research Annual Meeting 2023

EMERYVILLE, Calif., April 7, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced its participation at the American Association of Cancer Research (A...

2 months ago - PRNewsWire